Application of combined detection of tumor markers, serum pepsinogen, and gastrin-17 in thediagnosis of gastric cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XIONG Shimeng ^1,2 , XU Zipeng ¹ , NAN Yaqiang ¹ , CHEN Peng ³ , LI Hongtao ² ,  LIU Hongbin ^1,2

1. The Second Clinical Medical College of Lanzhou University, Lanzhou 730030, P. R. China;
2. The Department of General Surgery, Joint Logistic Support Force 940 Hospital of the People's Liberation Army, Lanzhou 730050, P. R. China;
3. The Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou 730000, P. R. China;

Corresponding author：

LIU Hongbin, Email: liuhongbin999@163.com

Keywords：

gastric cancer; carbohydrate antigen 19-9; carbohydrate antigen 72-4; carcinoembryonic antigen; pepsinogen; gastrin-17; combined detection

DOI：

10.7507/1007-9424.201903092

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the application value of the combined detection of CA19-9, CA72-4, carcinoembryonic antigen (CEA), serum pepsinogen Ⅰ(PGⅠ), serum pepsinogen Ⅱ(PGⅡ), ratio of PGⅠ and PGⅡ (PGR), and gastrin-17 (G17) in the diagnosis of gastric cancer.Methods One hundred cases of gastric cancer admitted to the Joint Logistic Support Force 940 Hospital of the People’s Liberation Army from January 2016 to August 2018 were respectively collected as the observation group, 110 cases of benign gastric lesions as the control group during the same period, the levels of serum CA19-9, CA72-4, CEA, PGⅠ, PGⅡ, PGR, and G17 were tested among patients in the two groups, the diagnostic value of single and combined detection (included CA19-9, CA72-4, CEA, PGⅠ, PGⅡ, PGR, and G17) were explored.Results The levels of CA19-9, CA72-4, CEA, and G17 in the observation group were higher than those of the control group (P<0.05), the levels of PGⅠ and PGR were lower than those of the control group (P<0.05). The positive detection rates of CA19-9, CA72-4, CEA, G17, PGⅠ, PGR, and combined detection in the observation group were all higher than those of the control group (P<0.05). The sensitivity and accuracy of the combined detection in the diagnosis of gastric cancer were higher than that of single serum index (P<0.05). The levels of serum CA19-9, CA72-4, CEA, and G17 in the patients of Ⅲ+Ⅳ period, low and moderate degree of differentiation, the tumor diameter was larger than five centimeters, signet-ring cell carcinoma, and distance metastasis of gastric cancer patients were on the high side compared with Ⅰ+Ⅱ period, high differentiation, the tumor diameter was less than or equal to five centimeters, glandular cancer, and no distance metastasis of gastric cancer patients, as well as the levels of serum PGⅠ and PGR on the low side (P<0.05).Conclusion The combined detection of CA19-9, CA72-4, CEA, PGⅠ, PGⅡ, PGR, and G17 can effectively improve the diagnose rate of gastric cancer, and they are closely related to the pathological characteristics of gastriccancer patients.

Citation： XIONG Shimeng, XU Zipeng, NAN Yaqiang, CHEN Peng, LI Hongtao, LIU Hongbin. Application of combined detection of tumor markers, serum pepsinogen, and gastrin-17 in thediagnosis of gastric cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(8): 923-928. doi: 10.7507/1007-9424.201903092 Copy

1.	杨励励. 2010-2013 年锦州市居民恶性肿瘤死亡原因分析. 中国卫生工程学, 2016, 15(1): 75-76.
2.	黄淼. 幽门螺杆菌在慢性胃病患者中感染的流行病学调查及影响其根除的相关因素. 中国卫生工程学, 2017, 16(4): 480-482.
3.	韦志鹃, 张晓云. 血清胃功能检测在早期胃癌筛查中的临床应用研究. 国际检验医学杂志, 2017, 38(16): 2240-2242.
4.	Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol, 2014, 12: 397.
5.	孙洁, 孟祥军. 血清 CA199、CEA、CA125、CA724 联合检测在胃癌诊断中的价值. 中国实验诊断学, 2014, 18(12): 1936-1939.
6.	Thapa A, Soares AC, Soares JC, et al. Carbon nanotube matrix for highly sensitive biosensors to detect pancreatic cancer biomarker CA19-9. ACS Appl Mater Interfaces, 2017, 9(31): 25878-25886.
7.	董晓微, 崔学强, 张俊华, 等. 血清肿瘤标志物 CA19-9、CA72-4、CEA、PGⅠ 联合检测对胃癌的诊断及预后价值分析. 国际检验医学杂志, 2018, 39(17): 2185-2188.
8.	杨卫. 血清肿瘤标志物 CEA、CA19-9、CA242、CA724 联合检测对胃癌的诊断效果分析. 数理医药学杂志, 2018, 31(1): 47-48.
9.	Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 2014, 17(1): 26-33.
10.	梁红. CA199、CEA 对判断胃癌转移与预后的应用价值. 中国卫生工程学, 2018, 17(3): 421-423.
11.	Deng K, Yang L, Hu B, et al. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14 651 patients. PLoS One, 2015, 10(4): e0124151.
12.	祝占奎, 黄泽平, 周亚雄, 等. 血清 CEA 及 CA19-9 水平与胃癌预后的关系. 包头医学院学报, 2018, 34(2): 10-12.
13.	曹晓莉, 张金业. 胃癌患者术后肿瘤标志物水平与临床预后的关系研究. 检验医学与临床, 2013, 10(16): 2133-2135.
14.	吕宾. 重视胃癌的筛查和早期诊断. 浙江医学, 2018, 40(14): 1521-1522, 1543.
15.	Tu H, Sun L, Dong X, et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study. Int J Cancer, 2015, 136(2): 425-434.
16.	Yanaoka K, Oka M, Mukoubayashi C, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev, 2008, 17(4): 838-845.
17.	陈卿奇, 羊文芳, 吴素江, 等. 血清胃蛋白酶原及胃泌素-17 水平与胃癌的相关性研究. 重庆医学, 2016, 45(35): 4938-4941, 4944.
18.	高洪亮, 李宁, 张清禄. 血清 PGⅠ、PGⅡ 及 G-17 检测在胃癌及萎缩性胃炎中的诊断价值分析. 癌症进展, 2017, 15(6): 654-656.
19.	Mishra P, Senthivinayagam S, Rana A, et al. Glycogen synthase kinase-3beta regulates snail and beta-catenin during gastrin-induced migration of gastric cancer cells. J Mol Signal, 2010, 5: 9.
20.	沈晨. 血清 PGⅠ、PGⅡ 及 G17 检测在早期胃癌筛查中的应用效果. 临床医学研究与实践, 2018, 3(27): 104-105.
21.	黄道桂, 任传路, 虞红艳, 等. 血清 PGⅠ, PGⅡ, TK1, TSGF, CEA 与 CA724 联合检测在胃癌诊断中的应用价值. 现代检验医学杂志, 2015, 30(1): 101-104.
22.	李迎今, 苏军燕, 徐长妍. 血清 CEA、PGR、G-17 检测在胃癌诊断中的价值分析. 中国实验诊断学, 2017, 21(9): 1498-1501.
23.	Kikuchi R, Abe Y, Iijima K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med, 2011, 223(1): 35-44.
24.	付爱琳, 张俊璇, 于琪力, 等. 血清胃泌素-17 联合胃蛋白酶原检测对胃癌诊断价值的临床研究. 世界最新医学信息文摘, 2018, 18(86): 155.
25.	黄树华, 张辉亮, 梁艺华, 等. CA72-4 与血清胃蛋白酶原比值对胃癌的鉴别诊断意义. 中国实用医药, 2018, 13(19): 32-33.

1. 杨励励. 2010-2013 年锦州市居民恶性肿瘤死亡原因分析. 中国卫生工程学, 2016, 15(1): 75-76.
2. 黄淼. 幽门螺杆菌在慢性胃病患者中感染的流行病学调查及影响其根除的相关因素. 中国卫生工程学, 2017, 16(4): 480-482.
3. 韦志鹃, 张晓云. 血清胃功能检测在早期胃癌筛查中的临床应用研究. 国际检验医学杂志, 2017, 38(16): 2240-2242.
4. Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol, 2014, 12: 397.
5. 孙洁, 孟祥军. 血清 CA199、CEA、CA125、CA724 联合检测在胃癌诊断中的价值. 中国实验诊断学, 2014, 18(12): 1936-1939.
6. Thapa A, Soares AC, Soares JC, et al. Carbon nanotube matrix for highly sensitive biosensors to detect pancreatic cancer biomarker CA19-9. ACS Appl Mater Interfaces, 2017, 9(31): 25878-25886.
7. 董晓微, 崔学强, 张俊华, 等. 血清肿瘤标志物 CA19-9、CA72-4、CEA、PGⅠ 联合检测对胃癌的诊断及预后价值分析. 国际检验医学杂志, 2018, 39(17): 2185-2188.
8. 杨卫. 血清肿瘤标志物 CEA、CA19-9、CA242、CA724 联合检测对胃癌的诊断效果分析. 数理医药学杂志, 2018, 31(1): 47-48.
9. Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 2014, 17(1): 26-33.
10. 梁红. CA199、CEA 对判断胃癌转移与预后的应用价值. 中国卫生工程学, 2018, 17(3): 421-423.
11. Deng K, Yang L, Hu B, et al. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14 651 patients. PLoS One, 2015, 10(4): e0124151.
12. 祝占奎, 黄泽平, 周亚雄, 等. 血清 CEA 及 CA19-9 水平与胃癌预后的关系. 包头医学院学报, 2018, 34(2): 10-12.
13. 曹晓莉, 张金业. 胃癌患者术后肿瘤标志物水平与临床预后的关系研究. 检验医学与临床, 2013, 10(16): 2133-2135.
14. 吕宾. 重视胃癌的筛查和早期诊断. 浙江医学, 2018, 40(14): 1521-1522, 1543.
15. Tu H, Sun L, Dong X, et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study. Int J Cancer, 2015, 136(2): 425-434.
16. Yanaoka K, Oka M, Mukoubayashi C, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev, 2008, 17(4): 838-845.
17. 陈卿奇, 羊文芳, 吴素江, 等. 血清胃蛋白酶原及胃泌素-17 水平与胃癌的相关性研究. 重庆医学, 2016, 45(35): 4938-4941, 4944.
18. 高洪亮, 李宁, 张清禄. 血清 PGⅠ、PGⅡ 及 G-17 检测在胃癌及萎缩性胃炎中的诊断价值分析. 癌症进展, 2017, 15(6): 654-656.
19. Mishra P, Senthivinayagam S, Rana A, et al. Glycogen synthase kinase-3beta regulates snail and beta-catenin during gastrin-induced migration of gastric cancer cells. J Mol Signal, 2010, 5: 9.
20. 沈晨. 血清 PGⅠ、PGⅡ 及 G17 检测在早期胃癌筛查中的应用效果. 临床医学研究与实践, 2018, 3(27): 104-105.
21. 黄道桂, 任传路, 虞红艳, 等. 血清 PGⅠ, PGⅡ, TK1, TSGF, CEA 与 CA724 联合检测在胃癌诊断中的应用价值. 现代检验医学杂志, 2015, 30(1): 101-104.
22. 李迎今, 苏军燕, 徐长妍. 血清 CEA、PGR、G-17 检测在胃癌诊断中的价值分析. 中国实验诊断学, 2017, 21(9): 1498-1501.
23. Kikuchi R, Abe Y, Iijima K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med, 2011, 223(1): 35-44.
24. 付爱琳, 张俊璇, 于琪力, 等. 血清胃泌素-17 联合胃蛋白酶原检测对胃癌诊断价值的临床研究. 世界最新医学信息文摘, 2018, 18(86): 155.
25. 黄树华, 张辉亮, 梁艺华, 等. CA72-4 与血清胃蛋白酶原比值对胃癌的鉴别诊断意义. 中国实用医药, 2018, 13(19): 32-33.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Application of combined detection of tumor markers, serum pepsinogen, and gastrin-17 in thediagnosis of gastric cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content